Pharmacokinetics and bioavailability of pyridinol carbamate in humans.
The pharmacokinetics of two pyridinol carbamate formulations were studied after a single oral administration in 10 healthy volunteers. An open one-compartment model described the evolution of plasma concentrations as a function of time. Pyridinol carbamate was rapidly absorbed (mean lag time from 0.36 to 0.38 hr). Its elimination half-life ranged from 3.3 to 7.9 hr. The two formulations were bioequivalent.
D000328:Adult; D001682:Biological Availability; D002219:Carbamates / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D011727:Pyridinolcarbamate / Q000097:blood / Q000378:metabolism*
D002219:Carbamates; D011727:Pyridinolcarbamate